Trade.Information

New studies showed that experimental drugs did not work and also had safety problems

The hot new strategy of trying to prevent heart disease by raising good cholesterol met more setbacks yesterday as new studies showed that experimental drugs did not work and also had safety problems.
The news followed Pfizer Inc.'s abandonment in December of an $800 million investment in torcetrapib, the leading contender in this class of drugs, because it raised the risk of heart attacks and deaths.

Heart specialists have been anxious to know whether the problems extend to all such drugs and doom this approach.

"A lot of people think it's the next big thing, and we'll need to understand what went wrong with torcetrapib to move forward," said Steven Nissen, a Cleveland Clinic heart specialist who is president of the American College of Cardiology.

The new studies, reported at the group's conference, gave a mixed answer. The Pfizer drug seems uniquely risky, but other drugs have problems, too.

And even though they and the Pfizer drug raised HDL, or good cholesterol, as intended, that made no difference in the odds of heart attacks or deaths, or key measures of cholesterol buildup in arteries.

Doctors long have focused on lowering LDL, or bad cholesterol, to cut the risk of heart attacks. Statins, sold as Lipitor and Zocor and also in generic form, lower LDL, which ferries fats from food into the bloodstream.

But many statin users suffer heart attacks anyway, so doctors have been trying to boost HDL, which transports fat from the blood to the liver to be disposed of, to further lower risk.

An extended-release niacin drug called Niaspan, sold by Kos Pharmaceuticals Inc., does this. But it can cause a prickly hot sensation called flushing that some people find intolerable. Pfizer, Merck & Co. Inc. and the Swiss drugmaker Roche Holding Ltd. are testing drugs that boost HDL in a novel way.

Yesterday, scientists reported the results of several studies on torcetrapib. In one, the drug boosted HDL 61 percent, but trends in death, hospitalization and heart attacks "are all going in the wrong direction," Nissen said.

An experimental diabetes drug by Eli Lilly & Co. that is 10,000 times more potent than fibrates, a current cholesterol treatment, also proved disappointing. The new drug raised HDL but also increased the risk of kidney, heart and other serious problems, Nissen reported.

Finally, infusions of a reconstituted form of HDL developed by CSL Ltd., an Australian company, made no big difference in the burden of artery buildups in a study led by Dr. Jean-Claude Tardif of the Montreal Heart Institute.

In several of these studies there were hints of some improvements in less important measures of artery buildup, which provides "a glimmer of hope for future development of this class of drugs," Dr. Alan Tall of Columbia University wrote in an editorial in the New England Journal of Medicine.